Results 121 to 130 of about 721 (146)

Venom variation and the future of antivenom design: Integrating population venomics, evolutionary toxinology, and precision therapeutics. [PDF]

Toxicon X
Dingwoke EJ.
europepmc   +1 more source

Varespladib Inhibits Secretory Phospholipase A2 in Bronchoalveolar Lavage of Different Types of Neonatal Lung Injury

Journal of Clinical Pharmacology, 2012
Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal
Ettore Domenico Capoluongo, Angelo Minucci, Daniele de Luca   +2 more
exaly   +8 more sources

Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients [PDF]

Journal of the American College of Cardiology, 2010
ObjectivesThe purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary syndrome patients.BackgroundSecretory phospholipase A2(sPLA2) represents a family of proatherogenic enzymes that hydrolyze ...
David Waters
exaly   +5 more sources

After FRANCIS: Next Steps in the Clinical Evaluation of Varespladib Methyl

Future Cardiology, 2011
Secretory phospholipase A2 (sPLA2) represents a family of isoenzymes that participate in lipoprotein and inflammatory pathways, mediate atherosclerosis and enhance myocardial ischemic injury.

exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Phospholipase A2 inhibitor varespladib prevents wasp sting-induced nephrotoxicity in rats

Toxicon, 2022
This study aimed to clarify whether varespladib, a phospholipase A2 (PLA2) inhibitor, can be used as a therapeutic agent for wasp sting-induced acute kidney injury (AKI). Rats were divided into control, AKI, and AKI + varespladib groups. The AKI model was established by subcutaneously injecting wasp venom at five different sites in rats.
Fengqi Hu
exaly   +3 more sources

Varespladib methyl in cardiovascular disease

Expert Opinion on Investigational Drugs, 2010
The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving evidence-based therapies has prompted investigations into complimentary treatments that may reduce residual risk. Analyses of clinical trials in statin-treated patients demonstrate that elevated lipid levels and an activated systemic inflammatory ...

exaly   +3 more sources

Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations

Toxicon, 2021
Varespladib (LY315920) is a synthetic phospholipase A2 (PLA2) inhibitor that has been demonstrating antiophidic potential against snake venoms that present PLA2 neurotoxins. In this study, we evaluate the capacity of Varespladib to inhibit the neuromuscular effects of crotoxin (CTX), the main toxic component of Crotalus durissus terrificus snake venom,
Walter Cavalcante, Consuelo L Fortes-Dias, Emylle Pinto   +2 more
exaly   +3 more sources

Varespladib: An Oral Treatment for Snakebite Envenoming

Journal of Current Toxicology and Venomics

Jessica Reid
exaly   +2 more sources

Varespladib (LY315920) neutralises phospholipase A2 mediated prothrombinase-inhibition induced by Bitis snake venoms

Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2020
Anticoagulant toxicity is a common function of venoms produced by species within the Bitis genus. Potent inhibition of the prothrombinase complex is an identified mechanism of action for the dwarf species B. cornuta and B. xeropaga, along with some localities of B. atropos and B. caudalis.
Bryan Fry, Nicholas Youngman, Andrew A Walker   +2 more
exaly   +6 more sources